Obtaining Regulatory T Cells from Uraemic Patients Awaiting Kidney Transplantation for Use in Clinical Trials

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2013 Apr 24

PMID 23607776

Citations 6

Authors

D Berglund

M Karlsson

A-R Biglarnia

T Lorant

G Tufveson

O Korsgren

B Carlsson

Affiliations

Soon will be listed here.

Abstract

Adoptive transfer of regulatory T cells (T(regs)) has been proposed for use as a cellular therapy to induce transplantation tolerance. Preclinical data are encouraging, and clinical trials with T(reg) therapy are anticipated. In this study, we investigate different strategies for the isolation and expansion of CD4(+) CD25(high) CD127(low) T(regs) from uraemic patients. We use allogeneic dendritic cells (DCs) as feeder cells for the expansion and compare T(reg) preparations isolated by either fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS) that have been expanded subsequently with either mature or tolerogenic DCs. Expanded T(reg) preparations have been characterized by their purity, cytokine production and in-vitro suppressive ability. The results show that T(reg) preparations can be isolated from uraemic patients by both FACS and MACS. Also, the type of feeder cells used in the expansion affects both the purity and the functional properties of the T(reg) preparations. In particular, FACS-sorted T(reg) preparations expanded with mature DCs secrete more interleukin (IL)-10 and granzyme B than FACS-sorted T(reg) preparations expanded with tolerogenic DCs. This is a direct comparison between different isolation techniques and expansion protocols with T(regs) from uraemic patients that may guide future efforts to produce clinical-grade T(regs) for use in kidney transplantation.

Citing Articles

Barriers to Treg therapy in Europe: From production to regulation.

Hennessy C, Deptula M, Hester J, Issa F Front Med (Lausanne). 2023; 10:1090721.

PMID: 36744143 PMC: 9892909. DOI: 10.3389/fmed.2023.1090721.

Ex vivo generation of regulatory T cells from liver transplant recipients using costimulation blockade.

Shimozawa K, Contreras-Ruiz L, Sousa S, Zhang R, Bhatia U, Crisalli K Am J Transplant. 2021; 22(2):504-518.

PMID: 34528383 PMC: 9078620. DOI: 10.1111/ajt.16842.

T cell plasticity in renal autoimmune disease.

Soukou S, Huber S, Krebs C Cell Tissue Res. 2021; 385(2):323-333.

PMID: 33937944 PMC: 8088832. DOI: 10.1007/s00441-021-03466-z.

Clinical Grade Regulatory CD4 T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.

Duggleby R, Danby R, Madrigal J, Saudemont A Front Immunol. 2018; 9:252.

PMID: 29487602 PMC: 5816789. DOI: 10.3389/fimmu.2018.00252.

A novel and rapid method to quantify Treg mediated suppression of CD4 T cells.

Long A, Tatum M, Mikacenic C, Buckner J J Immunol Methods. 2017; 449:15-22.

PMID: 28648384 PMC: 5573621. DOI: 10.1016/j.jim.2017.06.009.

References

Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A . Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002; 346(8):580-90. DOI: 10.1056/NEJMra011295. View

Wood K, Sakaguchi S . Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003; 3(3):199-210. DOI: 10.1038/nri1027. View

Matas A, Gillingham K, Humar A, Kandaswamy R, Sutherland D, Payne W . 2202 kidney transplant recipients with 10 years of graft function: what happens next?. Am J Transplant. 2008; 8(11):2410-9. PMC: 2766174. DOI: 10.1111/j.1600-6143.2008.02414.x. View

McMurchy A, Bushell A, Levings M, Wood K . Moving to tolerance: clinical application of T regulatory cells. Semin Immunol. 2011; 23(4):304-13. PMC: 3836227. DOI: 10.1016/j.smim.2011.04.001. View

Meier-Kriesche H, Schold J, Kaplan B . Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant. 2004; 4(8):1289-95. DOI: 10.1111/j.1600-6143.2004.00515.x. View

Peters J, Hilbrands L, Koenen H, Joosten I . Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS One. 2008; 3(5):e2233. PMC: 2376059. DOI: 10.1371/journal.pone.0002233. View

Fishman J . Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357(25):2601-14. DOI: 10.1056/NEJMra064928. View

Owens M, Maxwell J, Goodnight J, Wolcott M . Discontinuance of immunosuprression in renal transplant patients. Arch Surg. 1975; 110(12):1450-1. DOI: 10.1001/archsurg.1975.01360180020004. View

Page E, Dar W, Knechtle S . Tolerogenic therapies in transplantation. Front Immunol. 2012; 3:198. PMC: 3399382. DOI: 10.3389/fimmu.2012.00198. View

10.

Allan S, Broady R, Gregori S, Himmel M, Locke N, Roncarolo M . CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev. 2008; 223:391-421. DOI: 10.1111/j.1600-065X.2008.00634.x. View

11.

Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani C . Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010; 116(6):935-44. DOI: 10.1182/blood-2009-07-234872. View

12.

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

13.

Canavan J, Afzali B, Scotta C, Fazekasova H, Edozie F, Macdonald T . A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood. 2012; 119(8):e57-66. PMC: 3816350. DOI: 10.1182/blood-2011-09-380048. View

14.

Christensen L, Grunnet N, Rudiger N, Moller B, Birkeland S . Indications of immunological tolerance in kidney transplantation. Tissue Antigens. 1998; 51(6):637-44. DOI: 10.1111/j.1399-0039.1998.tb03006.x. View

15.

Bloor A, Thomson K, Chowdhry N, Verfuerth S, Ings S, Chakraverty R . High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007; 14(1):50-8. DOI: 10.1016/j.bbmt.2007.04.013. View

16.

Akyurek L, Johnsson C, Lange D, Georgii-Hemming P, Larsson E, Fellstrom B . Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants. Influence of Fas-mediated apoptosis. J Clin Invest. 1998; 101(12):2889-99. PMC: 508881. DOI: 10.1172/JCI1177. View

17.

Berglund D, Korsgren O, Lorant T, Schneider K, Tufveson G, Carlsson B . Isolation, expansion and functional assessment of CD4+CD25+FoxP3+ regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation. Transpl Immunol. 2011; 26(1):27-33. DOI: 10.1016/j.trim.2011.09.003. View

18.

Graca L, Cobbold S, Waldmann H . Identification of regulatory T cells in tolerated allografts. J Exp Med. 2002; 195(12):1641-6. PMC: 2193557. DOI: 10.1084/jem.20012097. View

19.

Newell K, Asare A, Kirk A, Gisler T, Bourcier K, Suthanthiran M . Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010; 120(6):1836-47. PMC: 2877933. DOI: 10.1172/JCI39933. View

20.

Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J . Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care. 2012; 35(9):1817-20. PMC: 3425004. DOI: 10.2337/dc12-0038. View